Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502.
Daniel G Stover, Roberto Salgado, Oleksander Savenkov, Karla Ballman, Erica L Mayer, Mark Jesus M Magbanua, Sherene Loi, Mark Vater, Kristyn Glover, Mark Watson, Yujia Wen, W Fraser Symmans, Charles Perou, Lisa A Carey, Ann H Partridge, Hope S Rugo
{"title":"Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502.","authors":"Daniel G Stover, Roberto Salgado, Oleksander Savenkov, Karla Ballman, Erica L Mayer, Mark Jesus M Magbanua, Sherene Loi, Mark Vater, Kristyn Glover, Mark Watson, Yujia Wen, W Fraser Symmans, Charles Perou, Lisa A Carey, Ann H Partridge, Hope S Rugo","doi":"10.1038/s41523-024-00683-x","DOIUrl":null,"url":null,"abstract":"<p><p>Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"75"},"PeriodicalIF":6.5000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339397/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-024-00683-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.
基质肿瘤浸润淋巴细胞（sTILs）与转移性乳腺癌（MBC）患者生存结果的关系仍不清楚。该研究的主要目的是评估随机III期试验CALGB 40502中sTILs与无进展生存期的关系。在控制治疗组的情况下，sTILs与接受化疗的MBC患者的无进展生存期和总生存期有关；但在额外调整激素受体状态后，这种影响并不显著。CALGB 现在是肿瘤临床试验联盟（Alliance for Clinical Trials in Oncology）的一部分。试验注册：ClinicalTrials.gov：NCT00785291。
期刊介绍：
npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
